TG THERAPEUTICS, INC. (TGTX): Results of Operations and Financial Condition
TG THERAPEUTICS, INC. (TGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_997107.htm EXHIBIT 99.1 ex_997107.htm Exhibit 99.1 TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI ® Revenue Guidance Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue o
How this was made
The 30-second read
Why it matters
The key tradable inputs are the raised FY2026 revenue and BRIUMVI U.S. net product revenue targets, plus clinical catalysts that could expand the addressable market and improve dosing convenience.
Market read
Traders can reprice TGTX on the same-day guidance raise and the disclosed clinical progress that supports future BRIUMVI uptake and regimen simplification.
What to watch
Operating expense guidance excludes non-cash comp and adds subcutaneous manufacturing and secondary manufacturer start-up costs, which could pressure margins if revenue ramp underperforms.
Background
This SEC 8-K reports Q2 2026 financial results and updates 2026 guidance, alongside multiple BRIUMVI clinical and development milestones.
Ticker impact
TG Therapeutics raised full-year 2026 revenue guidance and BRIUMVI U.S. net product revenue target after reporting Q2 results and clinical updates.
Bias upward with potential volatility around the next clinical readouts (ENHANCE full results and subcutaneous topline timing).
The filing discloses specific Q2 revenue figures, explicit FY2026 guidance increases, and new clinical topline/Phase 1 and trial initiation milestones tied to BRIUMVI commercialization and expansion.
Market effects
Reinforces investor appetite for commercial-stage biotech with expanding indications and regimen simplification, potentially improving read-through for immune-mediated disease peers.
Primarily US small/mid-cap biotech sentiment; limited direct regional spillover beyond healthcare growth factors.
Global revenue guidance and ex-US licensing royalties highlight international demand and partner economics, relevant for cross-border biotech sentiment.
Counterpoint
Despite the guidance raise, the company still faces execution risk around manufacturing scale-up for subcutaneous BRIUMVI and the timing/quality of upcoming Phase 3 and Phase 1/2 data.
Key entities
- issuerTG Therapeutics, Inc.
NASDAQ-listed company reporting Q2 2026 results and raising FY2026 guidance for BRIUMVI.
- productBRIUMVI (ublituximab-xiiy)
Core commercial asset driving revenue guidance and multiple clinical programs (RMS, subcutaneous formulation, myasthenia gravis, schizophrenia).
- clinical_programENHANCE trial
Phase 3 study in RMS where topline results showed bioequivalent exposure with a consolidated single infusion regimen.
- partnerNeuraxpharm
Ex-US licensing partner referenced for royalty and development-related revenue.
